Pharmafile Logo
Pharmafocus logo
Advanced Search

Amgen

Showing 15 posts of 216 posts found.

amgen_flag

Amgen’s novel KRAS inhibitor monotherapy shows promise at Phase 1 in advanced solid tumours

June 4, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Cancer, KRAS

Amgen has unveiled the first clinical data for its investigational KRAS inhibitor AMG 510, the first such therapy to reach …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

May 24, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Gilead, J&J, JJ, MSD, Sandoz, pharma, top ten

On the day that UK Prime Minister Theresa May announces her resignation, we look back on the week’s biggest stories …

News
amgen_flag

Amgen agrees to buy Nuevolution for $167 million

May 22, 2019
Research and Development Amgen, Cancer, Nuevolution, biotech, drug discovery, immuno-oncology, immunology, pharma

California biotech Amgen has agreed to buy Danish biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million). The …

News
fdaoutsideweb

FDA green lights Amgen and UCB’s Evenity in postmenopausal osteoporosis patients

April 10, 2019
Research and Development, Sales and Marketing Amgen, Evenity, FDA, UCB Pharma, osteoporosis, pharma

The FDA has decided to approve Amgen and UCB Pharma’s Evenity (romosozumab-aqqg) for the treatment of postmenopausal osteoporosis patients at …

News
x_ray_health_arm_doctors_medicine_bone_hospital_medical_insurance-480473

Osteoporisis risk in over half of European women over 70, three-quarters not treated, Amgen study finds

April 8, 2019
Research and Development, Sales and Marketing Amgen, Europe, UK, bones, osteoporosis, pharma, real world data, real-world data

A new study from Amgen analysing real-world data has revealed that more than half of European women over 70 years …

News
shutterstock_274590824

Jury upholds Amgen’s patent validity for Repatha, deflecting challenge from Sanofi and Regeneron

February 26, 2019
Manufacturing and Production, Sales and Marketing Amgen, Regeneron, Repatha, Sanofi, patent, pharma

Amgen is celebrating after a Delaware jury backed the validity of two of its patents against challenges from Regeneron and …

News
amgen_flag

China’s NMPA approves Amgen’s Repatha to reduce cardiovascular event risk

January 25, 2019
Medical Communications, Sales and Marketing Amgen, China, Repatha, cardiovascular disease, pharma, stroke

Amgen has announced that its proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor Repatha (evolocumab) has secured approval by China’s drug …

News
bonecells

Amgen and UCB’s Evenity approved in Japan for osteoporosis

January 9, 2019
Research and Development, Sales and Marketing Amgen, Japan, UCB Pharma, osteoporosis, pharma

Amgen has revealed that its bone-forming monoclonal antibody Evenity (romosozumab), developed in partnership with UCB Pharma, has been awarded approval …

News
amgen_flag

Amgen donate $2m towards increasing diversity in clinical trials

December 12, 2018
Research and Development Amgen, USA, clinical trials, diversity, donation

American multinational Amgen has teamed up with the Lazarex Cancer Foundation in support of an initiative aimed at increasing access …

News
amgen_flag

Amgen unveils double whammy of data for its investigational cancer immunotherapies at ASH 2018

December 5, 2018
Research and Development ASH 2018, Amgen, Cancer, acute myeloid leukaemia, myeloma, pharma

Amgen has presented the first clinical data at the American Society of Hematology (ASH) Annual Meeting 2018 for two investigational …

News
shutterstock_87495637

Pegfilgrastim greenlight marks eighth biosimilar approval in Europe for Sandoz

November 27, 2018
Manufacturing and Production, Sales and Marketing Amgen, Neulasta, Sanofi, Ziextenzo, biosimilars, pegfilgrastim, pharma

The European Commission has chosen to grant marketing authorisation to Ziextenzo, Sandoz’s biosimilar version of pegfilgrastim, better known as Amgen’s …

News
european_commission_web

Mundipharma’s Neulasta biosimilar approved in EU

November 26, 2018
Sales and Marketing Amgen, EU, Europe, Mundipharma, Neulasta, Pelmeg, pharma

Mundipharma has revealed that Pelmeg, its biosimilar version of Amgen’s Neulasta (pegfilgrastim), has been awarded marketing approval by the European …

News

GSK named third best UK workplace

October 22, 2018
Sales and Marketing AbbVie, Amgen, BMS, Eli Lilly, GSK, J&J, JJ, work

British multinational GlaxoSmithKline has been rated as the third best company to work for in the UK, according to jobs …

News

Samsung and Bioepis launch third Humira biosimilar in Europe

October 17, 2018
Research and Development, Sales and Marketing Amgen, Biogen, Humira, Imraldi, Samusng Bioepis, pharma

Hot on the heels of Amgen, Samsung Bioepis and Biogen have announced the launch of their own biosimilar version of …

News
amgen_flag

Amgen launches first biosimilar of best-selling Humira in Europe

October 16, 2018
Manufacturing and Production, Sales and Marketing Amgen, Amgevita, Humira, biosimilar, pharma

Amgen has announced the launch of a proprietary biosimilar version of Abbvie’s best-selling drug Humira (adalimumab) across all European markets, …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025